^
    Back
    Association details:
    Biomarker:MET elevation
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    ficlatuzumab (AV-299) (c-MET inhibitor, Hepatocyte growth factor inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Cancer
    Title:

    Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer

    Published date:
    06/11/2020
    Excerpt:
    This Phase I study evaluated the combination of cetuximab and ficlatuzumab, an anti-HGF mAb, in patients with recurrent/metastatic HNSCC...High circulating soluble cMet levels correlated with poor survival...Baseline levels of scMet were inversely associated with PFS (HR = 1.92; p = 0.048)...
    DOI:
    10.3390/cancers12061537
    Trial ID:
    NCT02277197